13 Best Multibagger Stocks to Invest in Now

12. Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Upside Potential:           245.96%

Aquestive Therapeutics (NASDAQ:AQST) stands out as a dynamic pharmaceutical company that has carved a distinct niche in the field of drug delivery innovation. Founded in 2004 in Warren, New Jersey, the company specializes in developing and commercializing advanced drug delivery systems designed to improve both absorption and patient convenience. Its flagship PharmFilm technology represents a groundbreaking approach to medication administration. Thin, dissolvable films created through this technology can be used sublingually (under the tongue), buccally (inside the cheek), or lingually (on the tongue), offering an alternative to traditional tablets or injections. This innovation not only enhances ease of use but also ensures faster and more reliable delivery of active ingredients, making it particularly beneficial for patients with difficulty swallowing or those requiring rapid onset of treatment.

Aquestive has leveraged its PharmFilm technology to build an impressive portfolio of FDA-approved treatments that address critical health conditions. Among its notable products are Libervant, designed to manage seizures; Sympazan, which provides relief for individuals with Lennox-Gastaut syndrome, a severe form of epilepsy; and Suboxone, a treatment aimed at combating opioid dependence. The company’s unique ability to merge pharmaceutical expertise with convenience-centric solutions has enabled it to establish a robust patent portfolio. Aquestive’s collaborations with leading pharmaceutical firms further cement its position in the global market, ensuring its innovative therapies reach a wider audience and bring meaningful improvements to patients’ lives.

Financially, Aquestive continues to demonstrate resilience and potential for growth. In the fourth quarter of 2024, the company reported revenues of $11.87 million, reflecting a year-over-year decline of 10.14%, but its full-year revenue of $55.2 million underscores steady progress in its proprietary PharmFilm technology. With secure cash reserves of $65.1 million, Aquestive is well-positioned to advance its drug pipeline and pursue ambitious research and development goals. Analysts remain optimistic about its prospects, forecasting a twelve-month average share price of $9.86, representing a remarkable upside potential of 245.96%. Aquestive Therapeutics is undoubtedly poised for significant advancements in the pharmaceutical industry.